Transgluteal MRI-targeted biopsy versus transrectal systemic biopsy in prostate cancer diagnosis
International Urology and Nephrology · 24.04.2025 · 57 (11) · 3499-3505
DOI: 10.1007/s11255-025-04522-1 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Urology and Nephrology, online erschienen am 24.04.2025. Verfasst von Zixi An und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Image-Guided Biopsy, Magnetic Resonance Imaging, Prostate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To compare the detection rate of clinically significant prostate cancer (csPCa) between transgluteal in-bore magnetic resonance imaging-targeted biopsy (MRI-TB) and transrectal ultrasonography biopsy (TRUSBx) in biopsy-naïve men, and which technique has lower complication rates. METHODS: From October 2021 to July 2024, clinical data were collected, retrospectively, from patients who underwent multiparameter MRI but had not previously undergone a prostate biopsy at hospital. The cases were considered based on the inclusion criteria. The patients were separated into two groups based on the prostate biopsy technique: TRUSBx (control group) and transgluteal MRI-TB (observation group). The csPCa detection and complications rates were compared between the two groups. RESULTS: We gathered data from 150 patients. A total of 91 patients participated, comprising 58 in the control group and 33 in the observation group. The detection rates of csPCa in the two groups were 27.3% and 22.4%, respectively (P > 0.05). Subsequent analysis revealed no significant difference in the csPCa detection rate between the two groups concerning various TPSA levels, lesion location, prostate volume, maximal lesion diameter, and PI-RADS score (P > 0.05). There were notable discrepancies in the occurrence of overall complications and hemorrhage between the two groups (P 0.05). CONCLUSION: Transgluteal MRI-TB can diminish complications while preserving csPCa detection rates. The evidence indicates that transgluteal MRI-TB is a more secure alternative for patients at elevated risk of infection and hemorrhage. And the pathway does not necessitate puncture tray or associated anesthetic management facilities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hebei Medical University, Shijiazhuang, China.
- Hebei Medical University, Shijiazhuang, China. sunpy9527@163.com.
- Department of Second Urology, Cangzhou Central Hospital, Xinghua West Road No.16, Yunhe District, Cangzhou, Hebei Province, China. sunpy9527@163.com.
- Department of Second Urology, Cangzhou Central Hospital, Xinghua West Road No.16, Yunhe District, Cangzhou, Hebei Province, China.
Zitieren
APA
An, Z., Sun, P., Liu, M., Li, J., Lin, C., Zhu, H., & Xue, R. (2025). Transgluteal MRI-targeted biopsy versus transrectal systemic biopsy in prostate cancer diagnosis. International Urology and Nephrology, 57(11), 3499-3505. https://doi.org/10.1007/s11255-025-04522-1
Vancouver
An Z, Sun P, Liu M, Li J, Lin C, Zhu H, et al. Transgluteal MRI-targeted biopsy versus transrectal systemic biopsy in prostate cancer diagnosis. International Urology and Nephrology. 2025;57(11):3499-3505. doi:10.1007/s11255-025-04522-1
BibTeX
@article{An2025,
author = {An, Zixi and Sun, Pengyu and Liu, Min and Li, Jianwei and Lin, Chenyu and Zhu, Huaxing and Xue, Runsong},
title = {Transgluteal MRI-targeted biopsy versus transrectal systemic biopsy in prostate cancer diagnosis},
journal = {International Urology and Nephrology},
year = {2025},
volume = {57},
number = {11},
pages = {3499--3505},
doi = {10.1007/s11255-025-04522-1}
}
EUVIMED